Extracorporeal blood purification therapy using Li's Artifical Liver System for patients with severe novel coronavirus pneumonia (COVID19) patient

Effecacy and safty of extracorporeal blood purification therapy for severe patients with novel coronavirus pneumonia (COVID19): a prospective cohort study

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000030503

Enrollment

Unknown

Registered

2020-03-05

Start date

2020-01-20

Completion date

Unknown

Last updated

2020-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Experimental group:Hemadsorption+conventional treatment

Control group:conventional treatment

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. aged >=18 years old; 2. laboratory conformed SARS-CoV-2 infection; 3. critically ill and require intensive care.

Exclusion criteria

Exclusion criteria: 1. pregnancy; 2. blood purification treatment prior to admission; 3. patients had other indications for blood purification treatment including hyperkalemia, acute kidney failure, and so on; 4. allergic to dimethyl sulfoxide, dextran or Heparin; 5. currently active malignant tumor or under Immunosuppressive therapy.

Design outcomes

Primary

Measure	Time frame
Mortality;	—

Secondary

Measure	Time frame
ICU stay period;Incubation period;IL-6;PaO2/FiO2 ratio;APACHE-II score;Pneumonia Severity Index;	—

Countries

China

Contacts

Public ContactXiaowei XU

The First Affiliated Hospital of Zhejiang University, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Disease

xxw69@126.com+86 13605708066

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026